Examples are somatostatin analogues directed towards the somatostatin receptor and ligands to target the prostate-specific membrane antigen (PSMA) to treat neuroendocrine tumours (NET) and prostate cancer, respectively. The gene discussed is FOLH1; the disease is neuroendocrine neoplasm.